Japanese maker of medical devices and pharmaceutical packaging, including glass vials, syringes and dialysis products.
Japanese maker of medical devices and pharmaceutical packaging, including glass vials, syringes and dialysis products.
Sells disposable medical products that hospitals reorder, such as syringes, needles and dialysis products, alongside glass vials and pre-filled syringes sold to drug companies, where regulatory qualification locks in orders. It also makes generic medicines.
In one line: A diversified med-device/pharma-packaging maker like a smaller Becton Dickinson.
Moat: narrow (scale, regulatory licence, installed base). Broad regulated manufacturing footprint and long qualification cycles with pharma customers.
Headquarters: Osaka, Japan · Founded: 1954 · Employees: 38,593
Size NIPRO (8086.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.68B, the 539th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,443 on 18 Nov 2026.
Performance Over six months the shares fell 11.0%, against +1.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 5.0% over the last twelve months (peer median +9.4%); the operating margin is 5.4% (peer median 13.6%).
Valuation It trades at 15.8× forward earnings against a peer median of 23.8× (5th cheapest of 19).
Capital Return on invested capital runs 2.4 points below its cost of capital (5.0% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥683B | ¥661B | ¥645B | ¥587B | ¥545B |
| Revenue growth | — | +2% | +10% | +8% | — |
| Gross profit | ¥215B | ¥213B | ¥194B | ¥174B | ¥166B |
| EBITDA | ¥101B | ¥101B | ¥92.2B | ¥81.2B | ¥66.5B |
| Net income | ¥10.8B | ¥13.5B | ¥5.11B | ¥11.1B | ¥4.58B |
| Free cash flow | n/a | -¥7.67B | -¥8.15B | -¥21.3B | -¥74.7B |
| Capital expenditure | n/a | ¥62.3B | ¥76.6B | ¥94.3B | ¥85.1B |
| Total debt | ¥660B | ¥638B | ¥632B | ¥630B | ¥596B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| NIPRO 8086.T | $1.68B | -11% | +5% | 5% | 15.8× | n/a |
| Becton Dickinson BDX | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% |
| Fresenius Medical Care FME.DE | $11.2B | +3% | -1% | 11% | 9.5× | -4.8% |
| Terumo 4543.T | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 8086.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.5% | -5.2% | 6th highest of 21 |
| 6-month return | -11.0% | +1.9% | 7th lowest of 21 |
| Distance from 52-week high | -18.0% | -26.7% | 6th highest of 21 |
| Revenue growth (TTM) | +5.0% | +9.4% | 8th lowest of 21 |
| Operating margin | 5.4% | 13.6% | 6th lowest of 21 |
| Forward P/E | 15.8× | 23.8× | 5th cheapest of 19 |
| ROIC minus cost of capital | -2.4 pp | +0.9 pp | 9th lowest of 21 |
| EV / EBITDA | 8.5× | 11.2× | 5th cheapest of 14 |
| Net debt / EBITDA | 5.3× | -1.0× | most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% | +3.3% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 16.4× | 2.7% | +23.4% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |